Terms: = Germ cell tumor AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546
741 results:
1. A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.
Du Z; Jiang Y; Yang Y; Kang X; Yan J; Liu B; Yang M
Sci Rep; 2024 Apr; 14(1):9427. PubMed ID: 38658591
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Model for High-Grade Neuroendocrine Carcinoma of the Lung Incorporating Genomic Profiling and Poly (ADP-ribose) Polymerase-1 Expression.
Kim HS; Kim JK; Lee JH; Lee YJ; Lee GK; Han JY
JCO Precis Oncol; 2024 Apr; 8():e2300495. PubMed ID: 38635931
[TBL] [Abstract] [Full Text] [Related]
3. Combined deletion of MEN1, atrx and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice.
Fuentes ME; Lu X; Flores NM; Hausmann S; Mazur PK
Sci Rep; 2024 Apr; 14(1):8510. PubMed ID: 38609433
[TBL] [Abstract] [Full Text] [Related]
4. STING is significantly increased in high-grade glioma with high risk of recurrence.
Zhong M; Long M; Han C; Ji S; Yang Q
Oncoimmunology; 2024; 13(1):2327682. PubMed ID: 38516268
[TBL] [Abstract] [Full Text] [Related]
5. Intratumoral histological and molecular heterogeneity in an adult diffuse glioma.
Yogaretnam T; Heffernan J; Leung R; Heeney C; Walsh A; Looby S; Caird J; Brett FM
Clin Neuropathol; 2024; 43(2):60-64. PubMed ID: 38495012
[TBL] [Abstract] [Full Text] [Related]
6. High-Grade Astrocytoma with Piloid Features: A Dual Institutional Review of Imaging Findings of a Novel Entity.
Soni N; Agarwal A; Ajmera P; Mehta P; Gupta V; Vibhute M; Gubbiotti M; Mark IT; Messina SA; Mohan S; Bathla G
AJNR Am J Neuroradiol; 2024 Apr; 45(4):468-474. PubMed ID: 38485198
[TBL] [Abstract] [Full Text] [Related]
7. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
[TBL] [Abstract] [Full Text] [Related]
8. Loss of miR-101-3p in melanoma stabilizes genomic integrity, leading to cell death prevention.
Lämmerhirt L; Kappelmann-Fenzl M; Fischer S; Meier P; Staebler S; Kuphal S; Bosserhoff AK
Cell Mol Biol Lett; 2024 Mar; 29(1):29. PubMed ID: 38431560
[TBL] [Abstract] [Full Text] [Related]
9. Patterns of T2-FLAIR discordance across a cohort of adult-type diffuse gliomas and deviations from the classic T2-FLAIR mismatch sign.
Malik P; Soliman R; Chen YA; Munoz DG; Das S; Bharatha A; Mathur S
Neuroradiology; 2024 Apr; 66(4):521-530. PubMed ID: 38347151
[TBL] [Abstract] [Full Text] [Related]
10. Application of PET imaging delta radiomics for predicting progression-free survival in rare high-grade glioma.
Ahrari S; Zaragori T; Zinsz A; Oster J; Imbert L; Verger A
Sci Rep; 2024 Feb; 14(1):3256. PubMed ID: 38332004
[TBL] [Abstract] [Full Text] [Related]
11. Molecular Determinants of Neurocognitive Deficits in Glioma: Based on 2021 WHO Classification.
Zhang K; Yang T; Xia Y; Guo X; Chen W; Wang L; Li J; Wu J; Xiao Z; Zhang X; Jiang W; Xu D; Guo S; Wang Y; Shi Y; Liu D; Li Y; Wang Y; Xing H; Liang T; Niu P; Wang H; Liu Q; Jin S; Qu T; Li H; Zhang Y; Ma W; Wang Y
J Mol Neurosci; 2024 Feb; 74(1):17. PubMed ID: 38315329
[TBL] [Abstract] [Full Text] [Related]
12. IDH1 mutation predicts seizure occurrence and prognosis in lower-grade glioma adults.
Tang T; Wang Y; Dai Y; Liu Q; Fan X; Cheng Y; Tang J; Xiao X; Shan Y; Wei P; Zhao G
Pathol Res Pract; 2024 Feb; 254():155165. PubMed ID: 38286053
[TBL] [Abstract] [Full Text] [Related]
13. Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells.
Chernov AN; Kim AV; Skliar SS; Fedorov EV; Tsapieva AN; Filatenkova TA; Chutko AL; Matsko MV; Galimova ES; Shamova OV
Cancer Chemother Pharmacol; 2024 May; 93(5):455-469. PubMed ID: 38280033
[TBL] [Abstract] [Full Text] [Related]
14. Interplay between atrx and IDH1 mutations governs innate immune responses in diffuse gliomas.
Hariharan S; Whitfield BT; Pirozzi CJ; Waitkus MS; Brown MC; Bowie ML; Irvin DM; Roso K; Fuller R; Hostettler J; Dharmaiah S; Gibson EA; Briley A; Mangoli A; Fraley C; Shobande M; Stevenson K; Zhang G; Malgulwar PB; Roberts H; Roskoski M; Spasojevic I; Keir ST; He Y; Castro MG; Huse JT; Ashley DM
Nat Commun; 2024 Jan; 15(1):730. PubMed ID: 38272925
[TBL] [Abstract] [Full Text] [Related]
15. GlioPredictor: a deep learning model for identification of high-risk adult IDH-mutant glioma towards adjuvant treatment planning.
Zheng S; Rammohan N; Sita T; Teo PT; Wu Y; Lesniak M; Sachdev S; Thomas TO
Sci Rep; 2024 Jan; 14(1):2126. PubMed ID: 38267516
[TBL] [Abstract] [Full Text] [Related]
16. Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms.
Cowzer D; Shah RH; Chou JF; Kundra R; Punn S; Fiedler L; DeMore A; Capanu M; Berger MF; Reidy-Lagunes D; Raj N
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38252063
[TBL] [Abstract] [Full Text] [Related]
17. Epidemiological and clinical analysis of exposure-related factors in non-melanoma skin cancer: A retrospective cohort study.
Artosi F; Costanza G; Di Prete M; Garofalo V; Lozzi F; Dika E; Cosio T; Diluvio L; Shumak RG; Lambiase S; Di Raimondo C; Campa S; Piscitelli P; Miani A; Bianchi L; Campione E
Environ Res; 2024 Apr; 247():118117. PubMed ID: 38218521
[TBL] [Abstract] [Full Text] [Related]
18. Novel alternative tools for metastatic pheochromocytomas/paragangliomas prediction.
Cui Y; Zhou Y; Gao Y; Ma X; Wang Y; Zhang X; Zhou T; Chen S; Lu L; Zhang Y; Chang X; Tong A; Li Y
J Endocrinol Invest; 2024 May; 47(5):1191-1203. PubMed ID: 38206552
[TBL] [Abstract] [Full Text] [Related]
19. [Practical application of immunohistochemistry in pancreatic neuroendocrine neoplasms : Tips and pitfalls].
Bräutigam K; Chouchane A; Konukiewitz B; Perren A
Pathologie (Heidelb); 2024 Feb; 45(1):35-41. PubMed ID: 38175232
[TBL] [Abstract] [Full Text] [Related]
20. Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These tumors Potential Candidates for Immune Checkpoint Blockade?
Mahajan S; Singh J; Dandapath I; Jha P; Chaturvedi S; Ahuja A; Bhardwaj M; Saran R; Garg A; Sharma MC; Manjunath N; Suri A; Sarkar C; Suri V
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):84-95. PubMed ID: 38158760
[TBL] [Abstract] [Full Text] [Related]
[Next]